aTyr Pharma, Inc. short interest in 2024
In 2024, aTyr Pharma, Inc.'s disclosed short interest ran from 0.30% of shares outstanding on 12 Jan 2024 to 4.34% on 31 Dec 2024, a change of +4.04 percentage points. The year's high was 4.34% on 31 Dec 2024 and its low 0.17% on 31 Jan 2024, averaging 1.24% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.34 days on 30 Sep 2024. Full history: aTyr Pharma, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.30% (12 Jan 2024)
- End of year
- 4.34% (31 Dec 2024)
- Change
- +4.04 pp
- High
- 4.34% (31 Dec 2024)
- Low
- 0.17% (31 Jan 2024)
- Average
- 1.24%
- Highest days to cover
- 4.34 (30 Sep 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.30% | 1.00 | |
| 31 Jan 2024 | 0.17% | 1.00 | |
| 15 Feb 2024 | 0.23% | 1.00 | |
| 29 Feb 2024 | 0.18% | 1.00 | |
| 15 Mar 2024 | 0.43% | 1.00 | 10-K filed, results (8-K) |
| 28 Mar 2024 | 0.64% | 1.00 | |
| 15 Apr 2024 | 0.57% | 1.07 | |
| 30 Apr 2024 | 0.94% | 1.90 | |
| 15 May 2024 | 0.51% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2024 | 0.52% | 1.06 | |
| 15 Aug 2024 | 0.46% | 1.08 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 0.58% | 1.70 | |
| 13 Sep 2024 | 0.90% | 1.83 | |
| 30 Sep 2024 | 1.80% | 4.34 | |
| 15 Oct 2024 | 1.41% | 1.00 | |
| 31 Oct 2024 | 2.19% | 1.24 | |
| 15 Nov 2024 | 2.52% | 2.62 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 2.59% | 2.74 | |
| 13 Dec 2024 | 3.48% | 4.33 | |
| 31 Dec 2024 | 4.34% | 3.80 |
See also: aTyr Pharma, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.